Trials / Terminated
TerminatedNCT06716190
A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 3731579 in Healthy Volunteers (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics and pharmacodynamics of BI 3731579 in healthy volunteers following administration of multiple rising doses per day over 15 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 3731579 | BI 3731579 |
| DRUG | Placebo matching BI 3731579 | Placebo matching BI 3731579 |
| DRUG | Midazolam | Midazolam |
Timeline
- Start date
- 2024-12-18
- Primary completion
- 2025-05-19
- Completion
- 2025-06-05
- First posted
- 2024-12-04
- Last updated
- 2026-03-17
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06716190. Inclusion in this directory is not an endorsement.